Navigation Links
STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
Date:7/15/2009

    ANTONY, France, July 15 /PRNewswire-FirstCall/ --

    Million EUR                   2008     08/07    2009     09/08
                              MEUR %Sales Var.% MEUR %Sales Var.%
    Southern Europe (1)        26.7   71    15  28.5   68     7
    Other EU countries (2)      9.3   24    20  11.4   28    23
    Other markets               2.0    5    47   1.5    4   (23)
    SLIT                       30.3   80    21  33.8   82    12
    SCIT                        6.1   16     7   5.9   14    (3)
    Other products              1.6    4     4   1.7    4     9
    Q2 sales                   38.0  100    18  41.4  100     9
    Southern Europe (1)        64.7   75    15  70.3   72     9
    Other EU countries (2)     18.6   21    18  24.1   25    30
    Other markets               3.7    4    46   3.2    3   (12)
    SLIT                       71.3   82    19  81.0   83    14
    SCIT                       12.3   14     4  12.8   13     4
    Other products              3.4    4     6   3.8    4    10
    H1 sales                   87.0  100    16  97.6  100    12

    (1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

HY1 sales

2nd quarter growth remained high at 9% (organic* 8%), but slowed down compared with the very strong start of the year. Sales growth over the first half-year remained strong at 12% (organic 11%), reflecting the continuing breakthrough of the sublingual route (+14%), which represented 83% of total sales.

The analysis by geographic region highlights the sharp increase of "Other EU countries" to 30% of sales, primarily due to the successful launch of Oralair(R) and the price increases introduced in Germany, as well as the transfer of the operations to a subsidiary in Switzerland.

Growth was more moderate in Southern Europe (up 9%). In addition to the consequences of weak pollen seasons in 2008, these markets appeared more affected by the economic crisis in a context of partial reimbursement (Italy and Spain).

The decline in "Other markets", a very diverse group whose performance is volatile, was mostly due to exceptional 2008 sales and foreign exchange effects.

HY1 highlights

5 years of research were rewarded in the 1st half-year 2009 with the positive results of the phase III clinical study carried out on the house dust mite desensitization tablet.

Moreover, the mutual recognition procedure for Oralair(R) (grass pollen desensitization tablet) started at an operational level and should lead to registration in most European countries by the end of 2009.

Outlook

The 1st half-year 2009 financial results, to be published on 26 August next after close of trading, should report a slight improvement over the 1st half-year 2008.

We confirm our previously issued full-year guidance of sales growth of about 10% and an operating profit maintained at the same high level as 2008, against a background of strong accompanying R&D investments.

Lastly, the second half-year will be marked by a particularly busy news flow: 3 Oralair(R) phase III studies (US, 3rd year of long-term study, protocol optimization), 1 phase IIb/III study on the birch pollen desensitization tablet, which for the first time includes a recombinant allergen, and 1 phase III Staloral(R) study on asthma, carried out in China.

Shareholders' agenda

The 2009 first half-year results will be presented on 27 August 2009 at 11.30am CET at Le Bristol hotel, 112, rue du Faubourg Saint-Honore, 75008 Paris, France.

A webcast of the meeting will be available both in French and English from 3pm.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% (gross) of its sales to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had sales of EUR 171 million and provided desensitization treatments to more than 500,000 patients.

    Euronext Paris (Compartment B)
    Component of SBF 120.
    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP

Additional financial information is available at: http://www.stallergenes.com

* Excluding foreign exchange effects


'/>"/>
SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: 2008: Strong Performance
2. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
3. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
4. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
5. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
6. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
7. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
8. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
9. Information warfare in the 21st century: Ideas are sometimes stronger than bombs
10. New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma
11. Web of Science(R) Renewals Remain Strong Despite Tough Economic Climate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... Feb. 3, 2016 New Jersey Health Foundation ... $1 million for researchers in New ... research that demonstrates exciting potential.   ... for the New Jersey Health Foundation Research Grant ... these educational institutions— Princeton University, Rutgers University, Rowan ...
(Date:2/3/2016)... , Feb. 3, 2016  Silk Therapeutics, Inc., today ... round. Silk Therapeutics has now raised a total of $10.25 ... by the company. The Series A2 round was led by ... , with participation from new investors Lear Corporation and ... and Roy P. Disney ; Richard Sackler , MD, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):